prismmarketview
Nov 19, 1:53 PM
$PVLA
Palvella unveils QTORIN™ docetaxel, a topical first-line program for Extramammary Paget’s Disease. EMPD is a rare skin cancer with no FDA-approved therapy, and an estimated 10,000+ U.S. patients have it.
FDA meeting planned for 1H 2027, then Phase 2.
https://prismmarketview.com/palvella-unveils-qtorin-docetaxel-aiming-for-the-first-fda-approved-therapy-in-rare-skin-cancer-empd/
0 replies